Purpose: The objective of this study was to evaluate the implementation of a Multidisciplinary Tumor Board (MDTB) strategy in the treatment of patients with uveal melanoma.Methods: A retrospective analysis was conducted on the implementation of MDTB meetings over a 24-month period. During this time, 72 intraocular tumors were discussed, including 59 confirmed cases of uveal melanoma. The MDTB involved a core group of specialists (e.g., ophthalmologists, oncologists, and radiologists), with other experts included when clinically appropriate. To assess patient satisfaction with the MDTB approach, a structured questionnaire was administered, including items on clarity of communication, perceived quality of care, and overall satisfaction, which were ranked on a 5-point scale.Results: A total of 319 patients with ocular, periocular, or orbital tumors were discussed during the study period, of which, 72 had intraocular tumors. A total of 13 (18%) were diagnosed to have choroidal metastases, whereas 59 (82%) had uveal melanomas. The average time between patient care and MDTB discussion was 15.9 days (IQR: 7.5–16.5). The mean time between the case discussion and the implementation of recommendations (diagnostic, therapeutic, or referral decisions) was 14.8 days (IQR: 6.0–23.75). Overall, 4 (7%) patients were classified as Stage I, 16 (27%) as Stage IIa, 18 (31%) as Stage IIb, 7 (12%) as Stage IIIa, 2 (3%) as Stage IIIb, and 12 (20%) as Stage IV. Regarding the satisfaction questionnaire, all patients (100%) agreed to have the clinical case discussed at the TB even though this could result in a delay in diagnostic/therapeutic implementation. However, only 60% of patients perceived they had been directly involved in the decision-making process.Conclusions: In selected cases of uveal melanoma and other types of cancer, MDTBs should be recognized as a gold standard in cancer care, allowing for comprehensive decision-making that draws on a wide range of highly specialized expertise.
目的：本研究旨在评估多学科肿瘤委员会（MDTB）策略在葡萄膜黑色素瘤患者治疗中的实施情况。方法：对为期24个月的MDTB会议实施情况进行回顾性分析。在此期间共讨论了72例眼内肿瘤病例，其中包含59例确诊的葡萄膜黑色素瘤。MDTB由核心专家团队（如眼科医生、肿瘤学家和放射科医生）组成，临床需要时可纳入其他专家。为评估患者对MDTB模式的满意度，采用结构化问卷进行调查，问卷项目涵盖沟通清晰度、感知护理质量和总体满意度，均采用5点量表进行评分。结果：研究期间共讨论319例眼部、眼周或眼眶肿瘤患者，其中72例为眼内肿瘤。13例（18%）诊断为脉络膜转移瘤，59例（82%）为葡萄膜黑色素瘤。患者就诊与MDTB讨论的平均间隔时间为15.9天（四分位距：7.5-16.5）。病例讨论与建议（诊断、治疗或转诊决策）实施的平均间隔时间为14.8天（四分位距：6.0-23.75）。总体分期情况：4例（7%）为I期，16例（27%）为IIa期，18例（31%）为IIb期，7例（12%）为IIIa期，2例（3%）为IIIb期，12例（20%）为IV期。满意度调查显示，尽管可能导致诊疗实施延迟，所有患者（100%）均同意在肿瘤委员会讨论其临床病例。然而，仅60%的患者认为自身直接参与了决策过程。结论：对于特定葡萄膜黑色素瘤及其他类型癌症病例，MDTB应被视为癌症诊疗的金标准，其能够整合多领域高度专业化知识，实现全面决策。
肿瘤(癌症)患者之家